Fig. 1

As of the follow-up date from January 1, 2021, to March 1, 2024, after treatment with 240 mg/d furmonertinib, 10 patients achieved PR and 1 patient achieved CR. The ORR was 52.4% (11/21). Lesions were stable in 9 patients, and in one case, the disease was stable but the lesion was not measurable. DCR: 100% (21/21)